


Testing Taskforce: New California COVID-19 cases, hospitalizations and deaths



Average test positivity past 7 days 6.1%, down 2.1% from last week

Cases are coming down from an early December peak

14 day average hospitalizations have plateaued and are starting to fall but are up about 2.5x the low in October

7 day average deaths remain at low levels.


- **Turnaround Time (for the week starting 01/08)**
- **93%** of PCR tests TAT < 1 day (2% increase from the previous week)
- **98%** of tests TAT < 2 days (1% increase from the previous week)
- *as of 01/23 -- Source: CalREDIE*

Jan 19 2022 with data as of Jan 17, 2022.

<https://covid19.ca.gov/state-dashboard/>

Daily new confirmed COVID-19 cases per million people

7-day rolling average. Due to limited testing, the number of confirmed cases is lower than the true number of infections.




COVID-19 cases are falling in countries around the world. In Japan, Hong Kong they are falling from a large peak. In the US and Australia cases are staying steady and in Europe including France cases are steady to falling from a peak.

Waning pop. immunity likely contributed to rise of cases in addition to new immune evasive variants
Highlighting the importance of booster vaccination.

Daily new confirmed COVID-19 deaths per million people

7-day rolling average. Due to varying protocols and challenges in the attribution of the cause of death, the number of confirmed deaths may not accurately represent the true number of deaths caused by COVID-19.

LINEAR LOG



Deaths are falling from a high level in Hong Kong and Japan. Deaths have increased in the US from 250per day to 600 per day

China situation update

SARSCoV2 Lineages in China

(12/25/22 to 1/5/23)

Nextclade pango	Sequence Count	% of Total
BA.5.2	249	29.93%
BF.7	230	27.64%
BQ.1.22	33	3.97%
Null	31	3.73%
BA.5.2.1	31	3.73%
BQ.1	23	2.76%
BQ.1.1	22	2.64%
XBB.1	16	1.92%
BA.5	16	1.92%
XBC	11	1.32%
BA.5.1	10	1.20%

- Number of sequences in GISAID is still **very low**, but limited data suggests that BA.5 lineages are dominant
- Several sublineages from China have already been proposed, but nothing particularly concerning


<https://public.tableau.com/app/profile/raj.rajnarayanan/viz/SARSCoV2Lineages-NextCladePANGO-China/Dashboard1>

@RajlabN

Visualization based on data in GISAID, re-analyzed in Nextclade for lineage assignment

Variant update

United States: 10/16/2022 – 1/21/2023



XBB.1.5

- XBB.1.5
- Fusion of BA.2.10.1.1 and BA.2.75.3.1.1.1
- Immune evasive, evades monoclonal antibodies
- Paxlovid still works
- Lineage has the greatest increase in growth in the US
- Highest number of cases in New York and East Coast

Paxlovid Resistance Currently Not Seen

- Currently we are **NOT** seeing signs of mutations in SARS-CoV-2 likely to impact the effectiveness of Paxlovid
- We are monitoring the genomic sequencing data for known Paxlovid resistance mutations

Figure 1. Percentage of Influenza Detections at Clinical Sentinel Laboratories, 2017–2023 Season to Date




Figure 13. Percentage of RSV Detections at Clinical Sentinel Laboratories, 2017–2023 Season to Date

